Norges Bank’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-974,050
| Closed | -$14.5M | – | 1945 |
|
|
2023
Q4 | $14.5M | Sell |
974,050
-133,565
| -12% | -$1.79M | ﹤0.01% | 1360 |
|
|
2023
Q3 | $17.9M | Buy |
1,107,615
+5,015
| +0.5% | +$145K | ﹤0.01% | 1271 |
|
|
2023
Q2 | $45.8M | Buy |
1,102,600
+25,682
| +2% | +$1.59M | 0.01% | 902 |
|
|
2023
Q1 | $64.8M | Buy |
1,076,918
+103,265
| +11% | +$8.25M | 0.01% | 719 |
|
|
2022
Q4 | $71.4M | Buy |
973,653
+20,090
| +2% | +$1.51M | 0.02% | 654 |
|
|
2022
Q3 | $72.5M | Buy |
953,563
+34,133
| +4% | +$2.66M | 0.02% | 625 |
|
|
2022
Q2 | $63.9M | Buy |
919,430
+26,469
| +3% | +$1.99M | 0.02% | 663 |
|
|
2022
Q1 | $74M | Buy |
892,961
+24,723
| +3% | +$1.82M | 0.02% | 697 |
|
|
2021
Q4 | $65.2M | Buy |
868,238
+45,949
| +6% | +$4.61M | 0.01% | 804 |
|
|
2021
Q3 | $95.5M | Buy |
822,289
+12,186
| +2% | +$1.84M | 0.02% | 634 |
|
|
2021
Q2 | $180M | Sell |
810,103
-2,031
| -0.3% | -$395K | 0.04% | 444 |
|
|
2021
Q1 | $107M | Sell |
812,134
-44,712
| -5% | -$7.07M | 0.02% | 612 |
|
|
2020
Q4 | $148M | Buy |
856,846
+29,899
| +4% | +$4.09M | 0.03% | 456 |
|
|
2020
Q3 | $92M | Buy |
826,947
+81,254
| +11% | +$6.5M | 0.02% | 569 |
|
|
2020
Q2 | $44.2M | Sell |
745,693
-32,000
| -4% | -$2.1M | 0.01% | 914 |
|
|
2020
Q1 | $52.4M | Hold |
777,693
| – | – | 0.02% | 676 |
|
|
2019
Q4 | $65.5M | Hold |
777,693
| – | – | 0.02% | 742 |
|
|
2019
Q3 | $58.2M | Sell |
777,693
-18,527
| -2% | -$1.48M | 0.02% | 784 |
|
|
2019
Q2 | $50.3M | Sell |
796,220
-82,615
| -9% | -$4.19M | 0.02% | 878 |
|
|
2019
Q1 | $42.3M | Buy |
878,835
+28,425
| +3% | +$1.37M | 0.01% | 964 |
|
|
2018
Q4 | $28.5M | Buy |
850,410
+29,726
| +4% | +$1.09M | 0.01% | 1156 |
|
|
2018
Q3 | $43M | Buy |
820,684
+61,686
| +8% | +$2.46M | 0.01% | 979 |
|
|
2018
Q2 | $23.8M | Hold |
758,998
| – | – | 0.01% | 1397 |
|
|
2018
Q1 | $16.5M | Buy |
758,998
+199,656
| +36% | +$4.29M | 0.01% | 1548 |
|
|
2017
Q4 | $11.3M | Buy |
559,342
+110,122
| +25% | +$2.12M | ﹤0.01% | 1701 |
|
|
2017
Q3 | $8.92M | Buy |
+449,220
| New | +$8.83M | ﹤0.01% | 1769 |
|
|
2016
Q2 | – | Sell |
-112,900
| Closed | -$1.64M | – | 2187 |
|
|
2016
Q1 | $1.64M | Buy |
112,900
+37,900
| +51% | +$544K | ﹤0.01% | 2010 |
|
|
2015
Q4 | $1.68M | Buy |
+75,000
| New | +$1.79M | ﹤0.01% | 2054 |
|
Other funds holding NVCR
Norges Bank's NVCR Position: Q1 2024 in Review
Norges Bank sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 974,050 shares — an estimated $14.5M sold.
Norges Bank first reported a position in NVCR in Q4 2015 and held it in 28 quarters. The position peaked at $180M in Q2 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.
- Norges Bank reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
- Norges Bank sold 974,050 NovoCure shares in Q1 2024, an estimated $14.5M.
- Norges Bank first reported a position in NovoCure in Q4 2015 and held it in 28 quarters.
- Norges Bank's NovoCure position peaked at $180M in Q2 2021.
- 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.
Based on Norges Bank's 13F filing for Q1 2024, filed 14 May 2024.